Paul Lammers

Dr. Lammers is a senior executive with more than 30 years of experience in the pharmaceutical and biotechnology industry. Dr. Lammers is the President and Chief Executive Officer of Triumvira Immunologics. Prior to joining Triumvira Immunologics, Dr. Lammers served as President & Chief Executive Officer of Mirna Therapeutics, where he raised approximately $160 million in funding before taking the company public on NASDAQ. Previously he was Chief Medical Officer of EMD Serono, a division of Merk KgaA. Additionally, Dr. Lammers held various executive and management roles with BioCyte Therapeutics, Zonagen, Hoechst Marion Roussel, and Organon International.

Dr. Lammers earned an M.D and M.S. in Biology and Reproductive Endocrinology from Radboud University in the Netherlands.